Skip to main content
TipRanks
Go Ultimate75% OFF

Cutia Therapeutics (2487) Stock Statistics & Valuation Metrics

2 Followers

Total Valuation

Cutia Therapeutics has a market cap or net worth of HKD 252.31M. The enterprise value is HKD 621.20M.

Market Cap
HKD 252.31M
Enterprise Value
HKD 621.20M

Share Statistics

Cutia Therapeutics has 376,583,700 shares outstanding. The number of shares has decreased by -2.65% in one year.

Shares Outstanding
376,583,700
Owned by Insiders
―
Owned by Institutions
<0.01%

Financial Efficiency

Cutia Therapeutics’s return on equity (ROE) is -0.38 and return on invested capital (ROIC) is -25.31%.

Return on Equity (ROE)
-0.38
Return on Assets (ROA)
-0.26
Return on Invested Capital (ROIC)
-25.31%
Return on Capital Employed (ROCE)
-0.30
Revenue Per Employee
1.25M
Profits Per Employee
-1.27M
Employee Count
268
Asset Turnover
0.26
Inventory Turnover
3.96

Valuation Ratios

The current PE Ratio of Cutia Therapeutics is -0.72. Cutia Therapeutics’s PEG ratio is -0.01.

PE Ratio
-0.72
PS Ratio
0.64
PB Ratio
0.29
Price to FCF
-0.92
Price to Operating Cash Flow
-0.91
PEG Ratio
-0.01

Income Statement

In the last 12 months, Cutia Therapeutics had revenue of 336.15M and earned -340.19M in profits. Earnings per share was -1.03.

Revenue
336.15M
Gross Profit
195.79M
Operating Income
-308.61M
Pretax Income
-340.19M
Net Income
-340.19M
EBITDA
-265.23M
Earnings Per Share (EPS)
-1.03

Cash Flow

In the last 12 months, operating cash flow was -226.70M and capital expenditures -4.75M, giving a free cash flow of -231.46M billion.

Operating Cash Flow
-226.70M
Free Cash Flow
-231.46M
Free Cash Flow per Share
-0.64

Dividends & Yields

Cutia Therapeutics pays an annual dividend of ―, resulting in a dividend yield of ―

Dividend Per Share
―
Dividend Yield
―
Payout Ratio
N/A
Free Cash Flow Yield
-108.43%
Earnings Yield
-136.09%

Stock Price Statistics

Beta
1.34
52-Week Price Change
-90.06%
50-Day Moving Average
0.94
200-Day Moving Average
2.99
Relative Strength Index (RSI)
37.69
Average Volume (3m)
521.43K

Important Dates

Cutia Therapeutics upcoming earnings date is Mar 30, 2027, TBA (Not Confirmed).

Last Earnings Date
Aug 31, 2026
Next Earnings Date
Mar 30, 2027
Ex-Dividend Date
―

Financial Position

Cutia Therapeutics as a current ratio of 3.87, with Debt / Equity ratio of 35.85%

Current Ratio
3.87
Quick Ratio
3.73
Debt to Market Cap
0.19
Net Debt to EBITDA
-0.20
Interest Coverage Ratio
-32.62

Taxes

In the past 12 months, Cutia Therapeutics has paid 0 in taxes.

Income Tax
0
Effective Tax Rate
0.00

Enterprise Valuation

Cutia Therapeutics EV to EBITDA ratio is -1.51, with an EV/FCF ratio of -1.45.

EV to Sales
1.01
EV to EBITDA
-1.51
EV to Free Cash Flow
-1.45
EV to Operating Cash Flow
-1.48

Balance Sheet

Cutia Therapeutics has HKD 626.38M in cash and marketable securities with HKD 274.17M in debt, giving a net cash position of HKD 352.21M billion.

Cash & Marketable Securities
HKD 626.38M
Total Debt
HKD 274.17M
Net Cash
HKD 352.21M
Net Cash Per Share
HKD 0.94
Tangible Book Value Per Share
HKD 1.94

Margins

Gross margin is 53.59%, with operating margin of -79.47%, and net profit margin of -84.59%.

Gross Margin
53.59%
Operating Margin
-79.47%
Pretax Margin
-83.84%
Net Profit Margin
-84.59%
EBITDA Margin
-66.72%
EBIT Margin
-79.47%

Analyst Forecast

The average price target for Cutia Therapeutics is ―, which is 11.43% higher than the current price. The consensus rating is ―

Price Target
―
Price Target Upside
―
Analyst Consensus
―
Analyst Count
―
Revenue Growth Forecast
35.47%
EPS Growth Forecast
46.42%

Scores

Smart Score
2
AI Score
44